Exciting Results from IceCure's ICE3 Trial
IceCure Medical Ltd. has just announced some promising results related to its ProSense® cryoablation technology, as detailed in the Annals of Surgical Oncology. This peer-reviewed study reveals an impressive 96.3% recurrence-free rate for women who underwent treatment for early-stage, low-risk breast cancer.
Encouraging News for Early-Stage Breast Cancer Patients
The insights shared in the study come at a crucial time, as IceCure gears up for an FDA Advisory Panel meeting where it will seek marketing approval for ProSense® in treating low-risk breast cancer. The trial included 194 patients who successfully received cryoablation treatment, and the outcomes were remarkable. Satisfaction levels soared, with 100% of patients and their treating physicians expressing happiness with the cosmetic results.
Safety and Efficacy of Cryoablation Treatment
Dr. Richard E. Fine, the lead author of the study, conveyed confidence in the safety and effectiveness of cryoablation using ProSense®. After five years, the ipsilateral breast tumor recurrence (IBTR) rate stood at a mere 4.3%, and breast cancer survival rates reached 96.7%. Among patients who received both cryoablation and endocrine therapy, the recurrence-free rate was a striking 96.3%.
Benefits of ProSense® Cryoablation
ProSense® stands out as a less invasive alternative to traditional surgical procedures like lumpectomy, which involve full anesthesia and lengthy recovery periods. Cryoablation can be performed under local anesthesia, resulting in minimal pain and scarring, which enhances recovery time. These advantages make ProSense® an appealing option for women seeking alternatives to more invasive surgical interventions.
Key Findings and Trial Results
- All 194 participants in the trial met the eligibility requirements and successfully underwent cryoablation treatments.
- The average age of participants was 74.9 years, with tumors averaging sizes of 7.4 mm in transverse and 8.1 mm in sagittal dimensions.
- There were no serious device-related adverse events reported during the trial.
- Patients exhibited a significant enhancement in their quality of life, supported by meaningful p-values indicating notable improvement.
- Overall, both patients and physicians reported 100% satisfaction with cosmetic outcomes.
About IceCure Medical
IceCure Medical, listed on Nasdaq with the ticker (NASDAQ: ICCM), focuses on developing innovative liquid-nitrogen-based cryoablation systems to treat both benign and malignant tumors. Their technology presents a minimally invasive option for various types of cancer, including those affecting the breast, kidney, bone, and lung.
Frequently Asked Questions
What is ProSense® Cryoablation?
ProSense® Cryoablation is a minimally invasive procedure that uses extreme cold to eliminate cancerous tumors. It serves as an alternative to conventional surgical methods for early-stage breast cancer.
What were the findings of the ICE3 trial?
The ICE3 trial highlighted a 96.3% recurrence-free rate, with patients and physicians reporting high satisfaction levels regarding the cosmetic results.
How does cryoablation differ from lumpectomy?
Unlike lumpectomy, which demands full anesthesia and a longer recovery time, cryoablation is a quicker, safer procedure with reduced pain and scarring.
What are IceCure Medical's next steps?
IceCure Medical is preparing for a meeting with the FDA Advisory Panel to discuss seeking marketing authorization for ProSense® in treating low-risk breast cancer.
Who is Dr. Richard E. Fine?
Dr. Richard E. Fine is the lead investigator of the ICE3 trial and is well-regarded for his significant contributions to breast surgery, having received numerous awards for his work.
